Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.
Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be active in the treatment of several hematologic malignancies, this review article is mostly focalized on its mode of action in multiple myeloma. The present paper is about the direct and indirect antitumor effects of lenalidomide on malignant plasmacells, bone marrow microenvironment, bone resorption and host's immune response. The molecular mechanisms and targets of lenalidomide remain largely unknown, but recent evidence shows cereblon (CRBN) as a possible mediator of its therapeutical effects.
Department of Oncohematology, University of Perugia, Santa Maria Hospital, 05100 Terni, Italy.
Roberta
R
Martiniani
Valentina
V
Di Loreto
Chiara
C
Di Sano
Alessandra
A
Lombardo
Anna Marina
AM
Liberati